TIDMOPTI
RNS Number : 9734H
OptiBiotix Health PLC
09 December 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Proposed Director appointment
Directorate change
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, a nn o unces that it intends to
appoint Christopher Brinsmead CBE as a Director of the Company,
subject to the completion of regulatory due diligence being carried
out by the Company's Nomad.
Chris has worked in the pharmaceutical industry for over 30
years, holding executive leadership roles with ICI, and Zeneca,
before becoming Chairman of AstraZeneca Pharmaceuticals UK,
President of AstraZeneca UK and Ireland (2001 - 2010), and
President of the Association of the British Pharamaceutical
Industry (ABPI) from 2008-2010. Since leaving executive roles,
Chris has taken on a number of advisory and Non-Executive Director
positions in private and public companies.
Advisory positions include independent advisor to the Prime
Minister and other senior government ministers for life sciences
(2010-2017) and advisor to Sodexo Healthcare (2010-2017). Chris is
currently the Chairman of two companies - Scapa Plc and Proveca
Ltd, and is a member of council at Imperial College.
Other non executive positions include UDG Healthcare plc (2017-
2019) and chairman of Consort Medical plc (2019-2020), a FTSE 350
company which was sold during Chris's leadership to Recipharm for
GBP505m in February 2020. Chris was Chairman of Collagen Solutions
plc from 2019 to 2020, leading its sale to Rosen's Diversified
Inc.. Chris was appointed a CBE in January 2015.
Chris will replace Peter Wennstrom as a director of the Company
on confirmation of his appointment. Peter will continue in an
advisory capacity for the Company following his resignation from
the Board.
A further announcement will be made in due course.
Neil Davidson, Chairman of OptiBiotix commented: "Chris's
appointment reflects the continued evolution of the Board as the
Company moves into the next phase of its development with its next
generation products, and explores a potential dual listing on
international markets. Chris's pharmaceutical, healthcare,
investment experience, and Chairmanship of a FTSE 350 company
complements the current Boards wealth of experience.
The Board of OptiBiotix would like to take this opportunity to
thank Peter for his advice on brand strategy and helping OptiBiotix
position its SlimBiome (R) , LP(LDL) (R) and WellBiome (R) brands
in international markets, and his contribution to the Company's
development.
The Company anticipate that there will be further additions and
changes to the Board and management teams as it continues to grow
sales, expand into international markets and commercialises its
next generation products. "
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the
content of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
Stephen O'Hara, Chief Executive below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding OptiBiotix's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABUBDDCSGDGGI
(END) Dow Jones Newswires
December 09, 2020 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
